Arsenic trioxide

Generic Name: Arsenic trioxide

Brand Names: Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac

Drug Type: Small Molecule

Chemical Formula: As_₂O_₃

CAS Number: 1327-53-3

Unique Ingredient Identifier: S7V92P67HO

Background: Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...

Indication: For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

Associated Conditions: Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia

Associated Therapies: -

Clinical Trials

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Phase 1

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Icotinib
Drug: Arsenic trioxide

First Posted Date: 2014-02-20

Last Posted Date: 2015-03-13

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 9

Registration Number: NCT02066870

Locations: 🇨🇳
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)

Interventions: Drug: arsenic trioxide
Other: laboratory biomarker analysis

First Posted Date: 2013-04-18

Last Posted Date: 2018-05-21

Lead Sponsor: Stanford University

Registration Number: NCT01835288

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

Phase 1

Completed

Conditions: Basal Cell Carcinoma of the Skin
Recurrent Skin Cancer

Interventions: Drug: arsenic trioxide

First Posted Date: 2013-02-15

Last Posted Date: 2018-06-08

Lead Sponsor: Stanford University

Target Recruit Count: 5

Registration Number: NCT01791894

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States

Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)

Phase 2

Terminated

Conditions: Systemic Lupus

Interventions: Drug: Arsenic trioxide

First Posted Date: 2012-11-30

Last Posted Date: 2016-01-06

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 11

Registration Number: NCT01738360

Locations: 🇫🇷
CHU de Marseille, Marseille, France
🇫🇷
Nantes University Hospital, Nantes, France
🇫🇷
CHRU de Strasbourg, Strasbourg, France

and more 3 locations

Study of Arsenic Trioxide in Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer
Cancer of Lung
Pulmonary Cancer
Pulmonary Neoplasms
Carcinoma, Small Cell

Interventions: Drug: Arsenic Trioxide

First Posted Date: 2011-11-11

Last Posted Date: 2021-02-17

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT01470248

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector

Phase 2

Completed

Conditions: Cancer Other Than Leukemia

Interventions: Drug: Arsenic Trioxide

First Posted Date: 2011-09-02

Last Posted Date: 2017-12-13

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 50

Registration Number: NCT01428128

Locations: 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Phase 2

Recruiting

Conditions: Acute Promyelocytic Leukemia With PML-RARA

Interventions: Drug: Arsenic Trioxide
Drug: Gemtuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Tretinoin

First Posted Date: 2011-08-04

Last Posted Date: 2024-05-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 151

Registration Number: NCT01409161

Locations: 🇺🇸
MD Anderson Regional Care Center-Bay Area, Nassau Bay, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson Regional Care Center-Katy, Houston, Texas, United States

and more 2 locations